Difference between revisions of "Antiphospholipid antibody syndrome"
Jump to navigation
Jump to search
Tag: visualeditor |
|||
| Line 34: | Line 34: | ||
| style="background-color:#ffffbf" |Seems not superior | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
| − | |[ | + | |[http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long Pengo et al. 2018] |
| − | |Phase III | + | | style="background-color:#1a9851" |Phase III (C) |
|Rivaroxaban | |Rivaroxaban | ||
| − | | | + | |Fewer events |
|} | |} | ||
| + | ''Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.'' | ||
====Therapy==== | ====Therapy==== | ||
*[[Warfarin (Coumadin)]] PO titrated to goal INR 2.0 to 3.0 | *[[Warfarin (Coumadin)]] PO titrated to goal INR 2.0 to 3.0 | ||
| Line 45: | Line 46: | ||
===References=== | ===References=== | ||
# Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. [https://www.nejm.org/doi/full/10.1056/NEJMoa035241 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13679527 PubMed] | # Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. [https://www.nejm.org/doi/full/10.1056/NEJMoa035241 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13679527 PubMed] | ||
| − | # Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018 Jul 21. [http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long | + | # Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018 Jul 21. [http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30002145 PubMed] |
[[Category:Antiphospholipid antibody syndrome regimens]] | [[Category:Antiphospholipid antibody syndrome regimens]] | ||
Revision as of 14:46, 17 July 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
1 regimens on this page
1 variants on this page
|
Guidelines
To be completed
All lines of therapy
Warfarin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Crowther et al. 2003 | Phase III (C) | High-intensity Warfarin (INR 3.1 to 4.0) | Seems not superior |
| Pengo et al. 2018 | Phase III (C) | Rivaroxaban | Fewer events |
Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.
Therapy
- Warfarin (Coumadin) PO titrated to goal INR 2.0 to 3.0
Continued indefinitely
References
- Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. link to original article PubMed
- Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018 Jul 21. link to original article PubMed